In the last trading session, 1.22 million shares of the Keros Therapeutics Inc (NASDAQ:KROS) were traded, and its beta was 1.40. Most recently the company’s share price was $10.49, and it changed around -$0.37 or -3.41% from the last close, which brings the market valuation of the company to $424.92M. KROS currently trades at a discount to its 52-week high of $73.00, offering almost -595.9% off that amount. The share price’s 52-week low was $9.77, which indicates that the current value has risen by an impressive 6.86% since then. We note from Keros Therapeutics Inc’s average daily trading volume that its 10-day average is 1.13 million shares, with the 3-month average coming to 1.54 million.
Keros Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.71. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 5 recommended KROS as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Keros Therapeutics Inc is expected to report earnings per share of -0.43 for the current quarter.
Keros Therapeutics Inc (NASDAQ:KROS) trade information
Instantly KROS has showed a red trend with a performance of -3.41% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 12.05 on recent trading dayincreased the stock’s daily price by 12.95%. The company’s shares are currently down -33.73% year-to-date, but still down -5.75% over the last five days. On the other hand, Keros Therapeutics Inc (NASDAQ:KROS) is -29.55% down in the 30-day period. We can see from the shorts that 4.02 million shares have been sold at a short interest cover period of 2.14 day(s).
The consensus price target as assigned by Wall Street analysts is $100, which translates to bulls needing to increase their stock price by 89.51% from its current value. Analyst projections state that KROS is forecast to be at a low of $96 and a high of $107.
Keros Therapeutics Inc (KROS) estimates and forecasts
The year-over-year growth rate is expected to be 21,125.47%, up from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 37.32M in revenue for the current quarter. 9 analysts expect Keros Therapeutics Inc to make 22.23M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 143k and 83k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 25,996.63%. Forecasts for the next quarter put sales growth at 26,687.14%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -111.11%. Keros Therapeutics Inc earnings are expected to increase by 0.22% in 2025, but the outlook is positive 5.74% per year for the next five years.
KROS Dividends
Keros Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Keros Therapeutics Inc (NASDAQ:KROS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.05% of Keros Therapeutics Inc shares, and 98.83% of them are in the hands of institutional investors. The stock currently has a share float of 100.89%. Keros Therapeutics Inc stock is held by 243.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 16.0279% of the shares, which is about 4.72 million shares worth $215.69 million.
BLACKROCK INC., with 8.5348% or 2.51 million shares worth $114.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
